BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/19/2021 11:15:33 AM | Browse: 327 | Download: 507
 |
Received |
|
2021-04-23 04:58 |
|
Peer-Review Started |
|
2021-04-23 05:01 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-06-13 13:29 |
|
Revised |
|
2021-07-31 06:20 |
|
Second Decision |
|
2021-10-29 09:57 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-10-31 18:12 |
|
Articles in Press |
|
2021-10-31 18:12 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-11-16 14:43 |
|
Publish the Manuscript Online |
|
2021-11-19 11:15 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Miwa Kawanaka, Ken Nishino, Hirofumi Kawamoto and Ken Haruma |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Miwa Kawanaka, MD, PhD, Associate Professor, Doctor, Department of General Internal Medicine 2, General Medical Center, Kawasaki Medical School, 2-6-1 Nakasange, Kita-ku, Okayama 700-8505, Japan. m.kawanaka@med.kawasaki-m.ac.jp |
| Key Words |
Hepatitis B; Immune tolerance; Immune-inactive; Anti-viral therapy; Hepatocellular carcinoma; Cirrhosis |
| Core Tip |
Hepatitis B virus (HBV) is a global health problem that causes acute and chronic infections and often leads to liver cirrhosis and hepatocellular carcinoma. Treatment of HBV is recommended for patients in the immunoactive hepatitis B surface-antigen-positive and -negative phases. Follow-up is recommended only for patients in the immune-inactive phase and the immune-tolerant phase, but opinion on this recommendation remain divided. This review discusses the major international guidelines for the treatment of chronic hepatitis B and highlights the importance of clinical factors for making decisions regarding the management of patients with HBV infection. |
| Publish Date |
2021-11-19 11:15 |
| Citation |
Kawanaka M, Nishino K, Kawamoto H, Haruma K. Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases. World J Gastroenterol 2021; 27(43): 7497-7508 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i43/7497.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i43.7497 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
